Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVBP ArriVent BioPharma	$19.21	$20.65	$15.47 ▼ $36.37	$779.35M	1.17	257,059 shs	149,509 shs
AVXL Anavex Life Sciences	$9.22 -2.4%	$10.52	$4.93 ▼ $14.44	$791.94M	0.8	1.11 million shs	779,652 shs
CGTX Cognition Therapeutics	$2.48 -19.0%	$0.92	$0.22 ▼ $3.83	$182.21M	1	4.95 million shs	13.86 million shs
TSHA Taysha Gene Therapies	$2.83 -4.7%	$2.65	$1.05 ▼ $3.31	$772.02M	0.98	2.89 million shs	1.85 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVBP ArriVent BioPharma	-1.94%	-0.31%	-8.22%	-8.52%	-30.70%
AVXL Anavex Life Sciences	-0.84%	-2.38%	-18.32%	+23.85%	+55.43%
CGTX Cognition Therapeutics	+6.99%	+51.49%	+327.91%	+1,130.89%	+338.40%
TSHA Taysha Gene Therapies	+0.34%	+3.48%	+11.24%	+8.00%	+38.79%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVBP ArriVent BioPharma	2.2976 of 5 stars	4.5	0.0	0.0	3.2	0.8	0.0
AVXL Anavex Life Sciences	3.7442 of 5 stars	3.5	1.0	4.7	2.1	0.8	0.6
CGTX Cognition Therapeutics	1.8053 of 5 stars	1.6	4.0	0.0	4.0	1.7	0.6
TSHA Taysha Gene Therapies	3.317 of 5 stars	4.5	2.0	0.0	2.3	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVBP ArriVent BioPharma	3.00	Buy	$39.14	103.76% Upside
AVXL Anavex Life Sciences	3.00	Buy	$44.00	377.22% Upside
CGTX Cognition Therapeutics	3.25	Buy	$2.83	14.25% Upside
TSHA Taysha Gene Therapies	3.00	Buy	$8.29	192.78% Upside

Current Analyst Ratings Breakdown

Latest CGTX, AVXL, TSHA, and AVBP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2025	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00
8/25/2025	AVBP ArriVent BioPharma	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/22/2025	AVXL Anavex Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00
8/18/2025	AVBP ArriVent BioPharma	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/13/2025	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00
8/13/2025	TSHA Taysha Gene Therapies	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$7.50 ➝ $8.00
8/12/2025	AVBP ArriVent BioPharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $42.00
8/12/2025	AVBP ArriVent BioPharma	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $33.00
8/12/2025	TSHA Taysha Gene Therapies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $10.00
8/8/2025	CGTX Cognition Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
8/4/2025	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	$6.16 per share	N/A
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	$1.06 per share	N/A
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	$0.10 per share	N/A
TSHA Taysha Gene Therapies	$8.33M	92.68	N/A	N/A	$0.91 per share	3.11

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVBP ArriVent BioPharma	-$80.49M	-$4.02	N/A	N/A	N/A	N/A	-55.40%	-51.97%	11/13/2025 (Estimated)
AVXL Anavex Life Sciences	-$43M	-$0.57	N/A	N/A	N/A	N/A	-45.67%	-40.21%	N/A
CGTX Cognition Therapeutics	-$33.97M	-$0.67	N/A	N/A	N/A	N/A	-251.23%	-130.75%	11/12/2025 (Estimated)
TSHA Taysha Gene Therapies	-$89.30M	-$0.34	N/A	N/A	N/A	-1,144.97%	-78.44%	-44.82%	11/12/2025 (Estimated)

Latest CGTX, AVXL, TSHA, and AVBP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q3 2025	AVXL Anavex Life Sciences	-$0.13	-$0.16	-$0.03	-$0.16	N/A	N/A
8/12/2025	Q2 2025	TSHA Taysha Gene Therapies	-$0.07	-$0.09	-$0.02	-$0.09	$1.61 million	$1.99 million
8/11/2025	Q2 2025	AVBP ArriVent BioPharma	-$0.70	-$0.90	-$0.20	-$0.90	N/A	N/A
8/7/2025	Q2 2025	CGTX Cognition Therapeutics	-$0.12	-$0.11	+$0.01	-$0.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	N/A
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	N/A
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVBP ArriVent BioPharma	N/A	12.74	12.74
AVXL Anavex Life Sciences	N/A	8.93	8.93
CGTX Cognition Therapeutics	N/A	1.54	1.54
TSHA Taysha Gene Therapies	0.17	12.48	12.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVBP ArriVent BioPharma	9.48%
AVXL Anavex Life Sciences	31.55%
CGTX Cognition Therapeutics	43.35%
TSHA Taysha Gene Therapies	77.70%

Insider Ownership

Company	Insider Ownership
AVBP ArriVent BioPharma	18.58%
AVXL Anavex Life Sciences	11.40%
CGTX Cognition Therapeutics	14.40%
TSHA Taysha Gene Therapies	3.78%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVBP ArriVent BioPharma	40	40.57 million	33.03 million	N/A
AVXL Anavex Life Sciences	40	85.89 million	76.10 million	Optionable
CGTX Cognition Therapeutics	20	73.47 million	62.89 million	Not Optionable
TSHA Taysha Gene Therapies	180	272.80 million	262.48 million	Optionable

CGTX, AVXL, TSHA, and AVBP Headlines

Recent News About These Companies

Piper Sandler Maintains a Buy on Taysha Gene Therapies (TSHA), Sets a PT of $9

August 25 at 12:26 AM | msn.com

Kovitz Investment Group Partners LLC Invests $407,000 in Taysha Gene Therapies, Inc. $TSHA

August 24, 2025 | marketbeat.com

Critical Analysis: Taysha Gene Therapies (NASDAQ:TSHA) and Targeted Medical Pharma (OTCMKTS:TRGM)

August 19, 2025 | americanbankingnews.com

FY2025 Earnings Forecast for TSHA Issued By Chardan Capital

August 19, 2025 | marketbeat.com

FY2025 Earnings Estimate for TSHA Issued By Chardan Capital

August 18, 2025 | americanbankingnews.com

Cantor Fitzgerald Issues Negative Forecast for TSHA Earnings

August 17, 2025 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up on Analyst Upgrade

August 15, 2025 | marketbeat.com

Wells Fargo & Company Increases Taysha Gene Therapies (NASDAQ:TSHA) Price Target to $8.00

August 15, 2025 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $10.00

August 14, 2025 | marketbeat.com

Taysha Gene Therapies price target raised to $14 from $11 at Canaccord

August 13, 2025 | msn.com

4TSHA : A Glimpse Into The Expert Outlook On Taysha Gene Therapies Through...

August 13, 2025 | benzinga.com

Taysha Gene Therapies (NASDAQ:TSHA) Issues Earnings Results

August 13, 2025 | marketbeat.com

Taysha Gene Therapies Inc (TSHA) Q2 2025 Earnings Call Highlights: Regulatory Milestones and ...

August 13, 2025 | finance.yahoo.com

XTX Topco Ltd Takes $282,000 Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

August 13, 2025 | marketbeat.com

Taysha Gene Therapies price target raised to $10 from $9 at Chardan

August 13, 2025 | msn.com

Taysha plans pivotal TSHA-102 trial enrollment in Q4 2025, extends cash runway to 2028

August 13, 2025 | msn.com

What's Next: Taysha Gene Therapies's Earnings Preview

August 13, 2025 | benzinga.com

Taysha Gene Therapies Advances Rett Syndrome Trials

August 12, 2025 | tipranks.com

Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Beats Revenue Estimates

August 12, 2025 | zacks.com

Taysha Gene Therapies, Inc. (TSHA) Q2 2025 Earnings Call Transcript

August 12, 2025 | seekingalpha.com

Taysha Gene Therapies, Inc. 2025 Q2 - Results - Earnings Call Presentation

August 12, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGTX, AVXL, TSHA, and AVBP Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

$19.21 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$19.58 +0.36 (+1.90%)

As of 05:16 PM Eastern

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Anavex Life Sciences NASDAQ:AVXL

$9.22 -0.23 (-2.43%)

Closing price 04:00 PM Eastern

Extended Trading

$9.16 -0.06 (-0.60%)

As of 05:34 PM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Cognition Therapeutics NASDAQ:CGTX

$2.48 -0.58 (-18.95%)

Closing price 04:00 PM Eastern

Extended Trading

$2.57 +0.09 (+3.59%)

As of 05:49 PM Eastern

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

Taysha Gene Therapies NASDAQ:TSHA

$2.83 -0.14 (-4.71%)

Closing price 04:00 PM Eastern

Extended Trading

$2.82 0.00 (-0.18%)

As of 05:48 PM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time